H.C. Wainwright analyst Arthur He lowered the firm’s price target on Adagene (ADAG) to $7 from $8 and keeps a Buy rating on the shares. The firm updated the company’s model to reflect delayed launches of ADG126.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
- Adagene Announces H1 2025 Financial Results and Strategic Developments
- Adagene initiated with an Outperform at Leerink
- Adagene Advances Clinical Plan for ADG126 in Colorectal Cancer After FDA Meeting
- Adagene announces regulatory update on development plan for muzastotug
- Adagene and ConjugateBio partner to develop antibody drug conjugate